Philip B. Rawlins

AstraZeneca (Brazil) — Brazil

Immunology and Microbiology · Life Sciences

19h-index1.8kcitations60works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Phagocytosis and Immune Regulation(10), Receptor Mechanisms and Signaling(8), Protein Degradation and Inhibitors(7), Monoclonal and Polyclonal Antibodies Research(6), PARP inhibition in cancer therapy(6)

Publications60 total

Discovery of Pyrimidoindolones as Novel Family VIII Bromodomain Binders
ACS Medicinal Chemistry Letters·2025· 1 cited
A TRIM21-based bioPROTAC highlights the therapeutic benefit of HuR degradation
Nature Communications·2023· 36 citedOpen Access
Design and Evaluation of a Low Hydrogen Bond Donor Count Fragment Screening Set to Aid Hit Generation of PROTACs Intended for Oral Delivery
Journal of Medicinal Chemistry·2023· 12 cited
Design of rigid protein–protein interaction inhibitors enables targeting of undruggable Mcl-1
Proceedings of the National Academy of Sciences·2023· 11 citedOpen Access
Abstract 6302: Structure-based and property-based drug design of AZD9574, a CNS penetrant PARP1 selective inhibitor and trapper
Cancer Research·2022· 1 cited
Surface Plasmon Resonance Screening to Identify Active and Selective Adenosine Receptor Binding Fragments
ACS Medicinal Chemistry Letters·2022· 9 citedOpen Access
Pharmacological inhibition of MERTK induces in vivo retinal degeneration: a multimodal imaging ocular safety assessment
Archives of Toxicology·2022· 17 citedOpen Access
Fragment screening at AstraZeneca: developing the next generation biophysics fragment set
RSC Medicinal Chemistry·2022· 12 citedOpen Access
Diverse Drug Combinations with an Eed Inhibitor Confer Context-Specific Benefit across Multiple Tumor Types
Blood·2021
Optimization of an Imidazo[1,2-<i>a</i>]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with <i>In Vivo</i> Efficacy
Journal of Medicinal Chemistry·2021· 27 citedOpen Access
Abstract 296: Structure-based and property-based drug design of AZD5305, a highly selective PARP1 inhibitor and trapper
Cancer Research·2021· 3 cited
Generating Selective Leads for Mer Kinase Inhibitors—Example of a Comprehensive Lead-Generation Strategy
Journal of Medicinal Chemistry·2021· 26 citedOpen Access
Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase
Bioorganic & Medicinal Chemistry Letters·2021· 20 citedOpen Access
Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibition
Nucleic Acids Research·2021· 60 citedOpen Access
Regenerable Biosensors for Small-Molecule Kinetic Characterization Using SPR
SLAS DISCOVERY·2020· 15 citedOpen Access
Complexities of a protonatable substrate in measurements of Hoechst 33342 transport by multidrug transporter LmrP
Scientific Reports·2020· 15 citedOpen Access
MerTK kinase domain in complex with a bisaminopyrimidine inhibitor
2020
MerTK kinase domain in complex with a type 2 inhibitor
2020
Research data supporting 'Complexities of a protonatable substrate in measurements of Hoechst 33342 transport by multidrug transporter LmrP'
Apollo (University of Cambridge)·2020Open Access
A-loop interactions in Mer tyrosine kinase give rise to inhibitors with two-step mechanism and long residence time of binding
Biochemical Journal·2020· 21 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Kevin J. Embrey(9), Erin Code(9), Marianne Schimpl(9), David Hargreaves(7), Jeffrey W. Johannes(7), Martin J. Packer(7), William McCoull(7), Alexander W. Hird(6), Ning Gao(6), Matthew A. Belmonte(5), Elisabetta Chiarparin(5), Michelle L. Lamb(5), Stephen E. Fawell(5), James Robinson(5), Sharan K. Bagal(5), Xiahui Zhu(5), Andrew D. Ferguson(5), E. Underwood(5), Steven L. Kazmirski(4), Nancy Su(4)